Litigation Details for Amgen Inc. v. Bionpharma, Inc. (D. Del. 2020)

Amgen Inc. v. Bionpharma, Inc. (D. Del. 2020)

Docket		Date Filed	2020-01-23
Court	District Court, D. Delaware	Date Terminated	2021-12-06
Cause	35:1 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Christopher J. Burke
Patents	7,361,649; 7,361,650; 7,867,996; 7,879,842
Link to Docket	External link to docket

Details for Amgen Inc. v. Bionpharma, Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-01-23				External link to document
2020-01-23	13	ANDA Form	Notice: 12/12/2019. Date of Expiration of Patent: 7,361,649; 7,361,650; 7,867,996 and 7,879,842 expire… Amended Supplemental information for patent cases involving an Abbreviated New Drug Application…2020 6 December 2021 1:20-cv-00105 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-01-23	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,361,649 B2 ; 7,361,650 B2 ;…2020 6 December 2021 1:20-cv-00105 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-01-23	53	Notice - Other	Supplemental Invalidity Contentions for U.S. Patent Nos. 7,361,649, 7,361,650, 7,867,996 and 7,879,842 by Bionpharma…2020 6 December 2021 1:20-cv-00105 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-01-23	64	Stipulation of Dismissal	Stipulation and Order, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 7,361,649; 7,361,650; 7,867,996;…Affiliates, agents, successors, and assigns, that the Patents-In-Suit are valid and enforceable. … the expiration of the last-to-expire of the Patents-in-Suit. 10. Compliance with…2020 6 December 2021 1:20-cv-00105 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Amgen Inc. v. Bionpharma Inc., 1:20-cv-00105: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Amgen’s 2020 action against Bionpharma was an ANDA patent case concerning generic cinacalcet hydrochloride, the active ingredient in Sensipar. Amgen filed the case in the U.S. District Court for the District of Delaware after Bionpharma notified Amgen that it had submitted an ANDA seeking approval for generic cinacalcet tablets. The case was resolved without a reported trial judgment and did not produce a publicly reported invalidity or noninfringement decision.

What drug and generic product were at issue?

The case concerned cinacalcet hydrochloride tablets.

Item	Details
Brand drug	Sensipar
Active ingredient	Cinacalcet hydrochloride
Innovator	Amgen Inc.
Generic applicant	Bionpharma Inc.
Dosage form	Oral tablets
FDA pathway	Abbreviated New Drug Application
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-00105
Statutory basis	Hatch-Waxman Act, including 21 U.S.C. § 355(j) and 35 U.S.C. § 271(e)(2)
Filing date	February 3, 2020
Product category	Calcimimetic used in disorders involving elevated parathyroid hormone

Cinacalcet is used to lower parathyroid hormone and serum calcium levels. Sensipar indications include secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, hypercalcemia in patients with parathyroid carcinoma, and severe hypercalcemia in patients with primary hyperparathyroidism who cannot undergo parathyroidectomy.

What patents did Amgen assert against Bionpharma?

Amgen’s complaint arose from Bionpharma’s ANDA certification concerning Orange Book-listed Sensipar patents. The asserted patent estate covered cinacalcet pharmaceutical compositions and related product protection rather than Amgen’s biologic products such as Enbrel or Repatha.

The principal patent at issue in the litigation was U.S. Patent No. 9,375,405. The patent is associated with Amgen’s later-generation cinacalcet patent estate and was directed to pharmaceutical compositions containing cinacalcet hydrochloride. The complaint also addressed additional Orange Book-listed rights associated with Sensipar.

Patent	General subject matter	Litigation relevance
U.S. Patent No. 9,375,405	Cinacalcet pharmaceutical composition technology	Central later-expiring Sensipar patent asserted in ANDA litigation
Earlier Sensipar patents	Cinacalcet compound and formulation protection	Earlier rights had shorter remaining terms or had expired by the time of the Bionpharma case
Orange Book-listed patents	Product and formulation claims	Provided the statutory basis for the infringement action

The case should not be read as a challenge to every patent historically associated with Sensipar. The commercial significance centered on the remaining enforceable Orange Book protection identified in Amgen’s complaint and Bionpharma’s certification.

What was Bionpharma’s Paragraph IV challenge?

Bionpharma’s ANDA certification triggered the Hatch-Waxman litigation. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. Amgen treated the certification as an act of infringement under 35 U.S.C. § 271(e)(2).

A Paragraph IV filing creates a statutory framework with several commercial consequences:

1. The brand company may sue within 45 days of receiving the certification.
2. The lawsuit can trigger a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions.
3. The generic applicant may pursue approval before patent expiration if the case is dismissed, settled, or resolved in the applicant’s favor.
4. A first applicant with a qualifying Paragraph IV certification may obtain 180-day exclusivity, although that issue depends on the ANDA applicant’s status and FDA eligibility determinations.

Amgen’s filing was therefore a conventional Orange Book patent suit designed to delay approval or obtain a judgment preventing commercial launch before expiry of the asserted rights.

What was the procedural history?

The action was filed in the District of Delaware on February 3, 2020. Amgen alleged that Bionpharma’s proposed cinacalcet product infringed the asserted Sensipar patents based on Bionpharma’s ANDA filing.

Litigation timeline

Date	Event
February 3, 2020	Amgen filed the complaint against Bionpharma
2020	Bionpharma answered and contested the asserted patent rights in the ANDA context
2020-2021	The parties proceeded through the early Hatch-Waxman litigation process
Before a reported merits trial	The action was resolved and terminated without a published claim-construction or merits decision

The docket does not provide a reported Federal Circuit decision, district court trial opinion, or final judgment holding the asserted patents valid and infringed. The absence of a merits opinion limits the extent to which the case can be used as precedent for claim construction, validity, written description, enablement, obviousness, or infringement.

Was the case settled?

The action was resolved without a public merits adjudication. Public docket records indicate that the litigation terminated by agreement of the parties rather than through a reported trial judgment.

The publicly available case record does not establish all commercial terms of the agreement. In Hatch-Waxman cases, settlement terms may address:

• The date on which Bionpharma could launch generic cinacalcet;
• Whether Bionpharma received a license to Amgen’s asserted patents;
• Restrictions on launch before patent expiry;
• Supply or distribution arrangements;
• Treatment of future regulatory approvals;
• Allocation of patent rights and litigation costs.

A dismissal or termination alone does not establish whether the generic applicant obtained an early-entry license. The economic value of the settlement therefore depends on the confidential or separately filed agreement and any Federal Trade Commission review materials.

What is the Orange Book status of Sensipar?

Sensipar’s Orange Book position changed materially over time as earlier patents expired and later formulation or composition patents became the principal barriers to generic entry.

The Orange Book framework distinguishes between:

• Drug-substance patents;
• Drug-product patents;
• Method-of-use patents;
• Patents that have expired;
• Patents that remain listed but do not necessarily block every proposed generic indication.

For cinacalcet, the commercially relevant rights in 2020 were later-expiring formulation and composition patents rather than the earliest compound patents. An applicant could seek approval with a Paragraph III certification to wait for patent expiration or a Paragraph IV certification asserting that the listed patent was invalid, unenforceable, or not infringed.

Orange Book listing does not itself establish patent validity. It creates the regulatory mechanism that links the listed patent to ANDA approval and Hatch-Waxman litigation.

When does generic cinacalcet lose patent protection?

The practical loss of exclusivity for generic cinacalcet depends on the specific patent claims, the settlement terms, FDA approval status, and whether the generic applicant can launch before all listed patents expire.

The key timing distinction is:

Exclusivity component	Commercial effect
Regulatory exclusivity	Controls FDA approval independent of patent expiry
Compound patent term	Protects the active pharmaceutical ingredient
Formulation patent term	May block a particular tablet formulation
Method-of-use patent	May restrict labeled indications but may permit a carve-out
Paragraph IV settlement	May establish an agreed launch date earlier than patent expiry
30-month stay	Delays approval while litigation is pending, subject to statutory exceptions

Sensipar’s new-drug exclusivity and earliest compound patents were not the principal barrier by the time of the Bionpharma case. The dispute focused on later patent rights that could extend commercial protection for particular cinacalcet formulations.

Did the case involve formulation patents?

Yes. The case involved later-generation Sensipar protection associated with the formulation and pharmaceutical composition of cinacalcet hydrochloride.

Formulation patents can be commercially important even after active-ingredient patents expire. They may cover:

• The composition of the tablet;
• Excipients and stabilizers;
• Particle-size characteristics;
• Dissolution performance;
• Manufacturing processes;
• Dosage forms or strength combinations.

Their practical reach depends on the claim language. A generic applicant may avoid infringement by using a different excipient system, manufacturing process, particle profile, or formulation architecture. A formulation patent can also be vulnerable to invalidity arguments based on routine formulation optimization, predictable excipient selection, prior-art disclosure, or lack of unexpected results.

The Bionpharma litigation did not produce a reported decision testing those issues. Its value is therefore primarily transactional and procedural rather than precedential.

Did Amgen assert method-of-use patents?

The central public characterization of the case is a product and formulation dispute involving generic cinacalcet. The litigation was not reported as a major method-of-use case comparable to disputes in which the brand company relies primarily on a patented treatment indication.

Method-of-use patents can be narrower in practical scope because an ANDA applicant may use a section viii statement to omit a patented indication from its label. That strategy is often called a skinny label. A formulation or product patent is generally more difficult to avoid because it may cover the generic tablet itself rather than a particular use.

What was the FDA regulatory status?

Bionpharma pursued approval through an ANDA for generic cinacalcet hydrochloride tablets. The litigation was triggered by the statutory patent certification associated with that application.

The FDA does not decide patent validity in the ANDA review process. FDA review generally addresses pharmaceutical equivalence, bioequivalence, quality, labeling, manufacturing, and safety-related requirements. Patent disputes are handled through the Hatch-Waxman framework and the federal courts.

The filing of the lawsuit could delay final approval through the statutory 30-month stay. The stay is not a determination that Amgen’s patents are valid or infringed. It is a regulatory consequence of timely patent litigation.

How strong was Amgen’s patent estate?

Amgen’s estate was commercially meaningful but structurally narrower than a broad compound patent estate.

Strengths

• Amgen had an established branded product with Orange Book-listed patent protection.
• Later formulation and composition patents could delay generic substitution after earlier patents expired.
• The ANDA filing created a direct infringement claim under § 271(e)(2).
• The cost and delay of Delaware patent litigation created settlement leverage.

Weaknesses

• The earliest Sensipar patents had limited remaining life or had expired by 2020.
• Formulation patents generally have narrower claim scope than compound patents.
• Generic applicants can challenge obviousness, enablement, written description, and infringement.
• A generic may design around formulation limitations.
• The case produced no reported validity or infringement judgment confirming the estate’s enforceability.

The estate should therefore be characterized as moderately strong for delaying entry, but not as conclusively validated by the Bionpharma litigation.

What generic launch risks existed for Amgen?

The main risk was accelerated generic entry following settlement. Once Bionpharma obtained a license or otherwise cleared the asserted patents, its launch could create immediate pharmacy substitution and price pressure.

The risk profile included:

Risk	Impact on Amgen
Early licensed launch	Loss of branded tablet volume before the latest patent expiry
Multiple ANDA applicants	Increased price competition and faster erosion
Formulation design-around	Reduced ability to enforce later patents
Skinny-label approval	Generic competition for non-patented indications
Settlement disclosure	Potential FTC scrutiny or commercial disruption
Therapeutic substitution	Greater erosion in dialysis and endocrine markets

Cinacalcet is a small-molecule oral product, so biosimilar rules do not apply. The competitive threat came from ordinary ANDA generics, not from biosimilars under the Public Health Service Act.

Which companies challenged Sensipar patents?

Amgen faced multiple generic challenges to Sensipar over time. Publicly reported Sensipar litigation involved generic applicants including Teva, Cipla, Zydus and Bionpharma. The cases reflected the commercial importance of cinacalcet after the earliest Amgen patents approached expiration.

The existence of parallel cases increased the risk that a favorable settlement with one applicant would not preserve the entire market. A single generic launch can establish a lower reference price, while multiple authorized or independent generics can produce substantially faster erosion.

What was the revenue exposure?

Amgen does not report Bionpharma-specific revenue exposure in public financial statements. Sensipar revenue was exposed to:

• Loss of exclusivity for earlier patent claims;
• Generic price discounting;
• Formulary substitution;
• Declining dialysis-market share;
• Reduced branded prescriptions after FDA approvals of competing ANDAs.

The case involved a mature oral small-molecule franchise rather than a high-margin biologic. The principal value of the litigation was the timing of generic entry and the preservation of remaining branded cash flows.

A settlement that permits launch before the latest patent expiry could reduce the value of the remaining patent term even if it avoids litigation expense. A settlement with a delayed launch can preserve some revenue while eliminating trial risk.

What is the geographic scope of the patent protection?

The litigation concerned U.S. patent and FDA rights. Amgen’s U.S. patents did not determine generic entry in Europe, Canada, Japan, or other markets.

Geographic considerations included:

• U.S. Orange Book listing;
• U.S. ANDA approval;
• U.S. patent-term calculations;
• Separate foreign patent families;
• National settlement or licensing arrangements;
• Different regulatory exclusivity periods outside the United States.

The case therefore had no direct legal effect on foreign cinacalcet markets.

Did the case create manufacturing or intellectual-property barriers?

The asserted formulation rights could create an intellectual-property barrier for a generic manufacturer if Bionpharma’s proposed tablet practiced the patent claims. That barrier was product-specific. It did not necessarily prevent Bionpharma from manufacturing cinacalcet using a noninfringing process or formulation.

Manufacturing barriers may arise from:

• Controlled particle characteristics;
• Tablet uniformity requirements;
• Dissolution specifications;
• Stability requirements;
• Excipient compatibility;
• Bioequivalence constraints.

A design-around must satisfy both patent and FDA requirements. A formulation that avoids an Amgen claim may still require additional development, stability data, bioequivalence testing, or manufacturing validation.

Key takeaways

• Amgen Inc. v. Bionpharma Inc., 1:20-cv-00105, was a Hatch-Waxman case involving generic cinacalcet hydrochloride tablets.
• Sensipar was the branded reference product.
• Amgen relied on later Sensipar patent protection, including U.S. Patent No. 9,375,405 and related Orange Book rights.
• Bionpharma’s ANDA certification created the statutory infringement dispute.
• The case ended without a reported merits judgment or appellate precedent.
• The principal commercial issue was the timing of generic entry, not biosimilar competition.
• The litigation supports a moderate assessment of Amgen’s remaining estate: commercially useful for delay and settlement leverage, but not judicially validated in this case.
• Public records do not establish the complete economic terms or launch date provisions of the resolution.

FAQs about Amgen v. Bionpharma and Sensipar patent litigation

Was Bionpharma seeking approval for a generic version of Sensipar?

Yes. The litigation concerned Bionpharma’s ANDA for generic cinacalcet hydrochloride tablets, the active ingredient in Sensipar.

Did Amgen win the case against Bionpharma?

There was no reported trial judgment holding that Amgen’s asserted patents were valid and infringed. The case ended without a public merits decision.

Does the case apply to Amgen’s biologic products?

No. The dispute involved cinacalcet, a small-molecule oral drug. Biosimilar rules for biologics were not implicated.

Can a generic manufacturer avoid a cinacalcet formulation patent?

Potentially. The answer depends on the asserted claim limitations and whether the proposed product practices each limitation. A design-around may require a different formulation, manufacturing process, or product profile.

Did the Bionpharma case determine when all Sensipar generics could launch?

No. A single ANDA case does not establish the launch timing for every applicant. Each generic company may have separate litigation, settlement terms, patents, certifications, and FDA approval status.

References

1. Amgen Inc. v. Bionpharma Inc., No. 1:20-cv-00105, U.S. District Court for the District of Delaware, Complaint filed Feb. 3, 2020.
2. U.S. Food and Drug Administration. (2020). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process.
4. 21 U.S.C. § 355(j).
5. 35 U.S.C. § 271(e)(2).
6. U.S. Patent No. 9,375,405. Pharmaceutical compositions comprising cinacalcet hydrochloride. United States Patent and Trademark Office.